Glioblastoma Multiforme Multipeptide Vaccine IMA950

Drug Overview

The Glioblastoma Multiforme Multipeptide Vaccine IMA950 is a modern form of cancer treatment designed to help the body’s own defense system fight brain tumors. In the medical world, it is classified as a Targeted Immunotherapy. Unlike traditional vaccines that prevent diseases like the flu, this is a “therapeutic vaccine,” meaning it is given to patients who already have a diagnosis to help stop the cancer from growing or returning.

IMA950 is often referred to as a “Smart Drug” because it is highly specific. It contains several tiny pieces of proteins, called peptides, that are found almost exclusively on the surface of glioblastoma cells. By teaching the immune system to recognize these specific markers, the vaccine helps the body distinguish between dangerous tumor cells and healthy brain tissue.

• Generic Name: IMA950
• US Brand Names: None (Currently an investigational drug)
• Drug Class: Cancer Vaccine; Multipeptide Immunotherapy
• Route of Administration: Intradermal (Injection into the skin)
• FDA Approval Status: Investigational (Currently in Clinical Trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how IMA950 works, imagine that a cancer cell is wearing a specific “uniform” that makes it different from a healthy cell. This uniform consists of proteins called Tumor-Associated Antigens (TAAs). IMA950 is composed of 11 different synthetic peptides that match the proteins found on glioblastoma cells.

At the molecular level, the vaccine works through a process called T-cell Activation:

1. Recognition: When IMA950 is injected into the skin, specialized immune cells called Antigen-Presenting Cells (APCs) “eat” the peptides.
2. Display: The APCs travel to the lymph nodes and “show” these peptides to T-cells (the body’s “soldier” cells). The peptides are held by a “hand” on the cell surface called the MHC (Major Histocompatibility Complex).
3. Priming: This process trains two types of soldiers: CD8+ Cytotoxic T-cells, which kill cancer cells directly, and CD4+ Helper T-cells, which act as generals to coordinate the attack.
4. The Hunt: Once trained, these T-cells travel through the blood and cross the blood-brain barrier. They seek out any cell displaying those specific 11 protein markers.
5. Destruction: When a T-cell finds a glioblastoma cell, it releases chemicals that punch holes in the cancer cell’s wall, causing it to die without harming the surrounding healthy brain cells.

FDA-Approved Clinical Indications

As an investigational drug, IMA950 is currently only available to patients enrolled in approved clinical trials. It is not yet approved for general use.

Oncological Uses (Investigational)

• Newly Diagnosed Glioblastoma Multiforme (GBM): Used as an add-on treatment after surgery and initial radiation.
• Recurrent Glioblastoma: Studied in patients whose brain tumors have returned after previous therapy.
• Astrocytoma: Investigated for use in other high-grade gliomas.

Non-Oncological Uses

• There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

IMA950 is administered as a series of injections into the skin. It is usually given alongside an “adjuvant” (a helper substance like GM-CSF) to make the immune response stronger.

Dose Adjustments:

• Renal/Hepatic Insufficiency: Since the vaccine works through the immune system and is not processed primarily by the liver or kidneys like chemical drugs, specific dose adjustments for organ failure are not currently standardized.

Clinical Efficacy and Research Results

Recent clinical data (2020-2025) has looked at how well IMA950 works when combined with standard care (the “Stupp Protocol”).

• Immune Response Rates: Studies have shown that over 90% of patients treated with IMA950 developed a measurable immune response against at least one of the peptides in the vaccine.
• Survival Data: In Phase I/II trials, patients receiving the vaccine showed a Median Overall Survival of approximately 15 to 19 months. While this is promising, researchers are working on combinations to extend this further.
• Disease Progression: Numerical data suggests that the “Progression-Free Survival” (time before the tumor grows again) can be slightly improved when IMA950 is used alongside modern immunotherapies like Pembrolizumab.

Safety Profile and Side Effects

IMA950 is generally considered very safe because it targets cancer cells specifically, causing very few of the “whole-body” side effects seen with chemotherapy.

Black Box Warning:

None. (Investigational vaccines typically do not have Black Box Warnings).

Common Side Effects (>10%)

• Injection Site Reaction: Redness, swelling, or a small bump where the needle went in.
• Fatigue: Feeling unusually tired.
• Flu-like Symptoms: Mild fever, chills, or muscle aches.
• Headache: Mild to moderate head pain.

Serious Adverse Events

• Allergic Reaction: Rare instances of severe itching or trouble breathing (Anaphylaxis).
• Brain Swelling (Edema): Rarely, the immune attack can cause temporary inflammation in the brain, which is monitored by MRI.

Management Strategies

• For Site Reactions: Use a cold compress or over-the-counter anti-itch cream.
• For Flu Symptoms: Standard fever reducers (like Acetaminophen) are usually effective.

Research Areas

IMA950 is a major focus in Immunotherapy research. Scientists are currently testing if combining IMA950 with Checkpoint Inhibitors (drugs that “take the brakes off” the immune system) makes the vaccine significantly more powerful. There is also early research into using IMA950 to prime the brain environment before Stem Cell-derived NK Cell therapy, creating a multi-layered attack against the most aggressive brain tumors.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• HLA-Typing: This blood test is mandatory. Because of how the vaccine works, it only functions in patients with a specific “immune type” (usually HLA-A*02).
• MRI Scan: To establish a baseline measurement of the tumor.
• Immune Panel: To check the health of your white blood cells.

Precautions During Treatment

• Steroid Use: High doses of steroids (like Dexamethasone) can “shut down” the immune system. Your doctor will try to keep these at the lowest dose possible while you receive the vaccine.
• Skin Care: Do not apply lotions or creams to the injection site for 24 hours.

“Do’s and Don’ts” List

• Do stay hydrated and rest on the day of your injection.
• Do tell your doctor immediately if you have a sudden seizure or new weakness.
• Don’t assume a “bump” at the injection site is an infection; it is usually a sign that your immune system is reacting to the vaccine.
• Don’t skip your monthly booster shots, as the immune system needs constant “reminders” to fight the cancer.

Legal Disclaimer

Standard Medical Information Disclaimer: This guide is for informational purposes only and does not constitute medical advice. IMA950 is an investigational drug and is only available through clinical trials. Always consult with a licensed oncologist or neurosurgeon to discuss treatment options, risks, and benefits specific to your medical history. Data reflects clinical information available as of early 2026.